Drug Trial Radar · NCT02101866
A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: May 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 2014
Primary completion
May 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Biota Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study aims to determine the oral bioavailability of a single dose of a new vapendavir tablet formulation and compare it to that of the previous vapendavir capsule formulation. The safety of both drug products will also be assessed.
Conditions
- Healthy
Interventions
Vapendavir 300 mg tabletDrug
tablet - single dose
Vapendavir 132 mg capsulesDrug
2 capsules - single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Systemic exposure profile of a single dose of a vapendavir 300 mg tablet compared to the exposure profile following a single dose of two 132 mg vapendavir capsulesTime frame: maximum up to 46 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigative Site
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.